Log In
Print
BCIQ
Print
Print this Print this
 

lesinurad (RDEA594)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionSelective solute carrier family 22 organic anion urate transporter member 12 (SLC22A12; URAT1) inhibitor
Molecular Target Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (URAT1)
Mechanism of ActionUrate transporter 1 (URAT1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationHyperuricemia / gout
Indication DetailsTreat allopurinol-refractory gout; Treat gout; Treat hyperuricemia in patients with gout
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,300.0M

$1,300.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today